These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 34617309)

  • 1. Intermittent versus daily regimen of prednisolone in ambulatory boys with Duchenne muscular dystrophy: A randomized, open-label trial.
    Kochar GS; Sondhi V; Kabra SK; Yadav SL; Dwivedi SN; Gulati S
    Muscle Nerve; 2022 Jan; 65(1):60-66. PubMed ID: 34617309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Corticosteroids for the treatment of Duchenne muscular dystrophy.
    Matthews E; Brassington R; Kuntzer T; Jichi F; Manzur AY
    Cochrane Database Syst Rev; 2016 May; 2016(5):CD003725. PubMed ID: 27149418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
    Manzur AY; Kuntzer T; Pike M; Swan A
    Cochrane Database Syst Rev; 2008 Jan; (1):CD003725. PubMed ID: 18254031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
    Manzur AY; Kuntzer T; Pike M; Swan A
    Cochrane Database Syst Rev; 2004; (2):CD003725. PubMed ID: 15106215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial.
    Guglieri M; Bushby K; McDermott MP; Hart KA; Tawil R; Martens WB; Herr BE; McColl E; Speed C; Wilkinson J; Kirschner J; King WM; Eagle M; Brown MW; Willis T; Griggs RC; ; Straub V; van Ruiten H; Childs AM; Ciafaloni E; Shieh PB; Spinty S; Maggi L; Baranello G; Butterfield RJ; Horrocks IA; Roper H; Alhaswani Z; Flanigan KM; Kuntz NL; Manzur A; Darras BT; Kang PB; Morrison L; Krzesniak-Swinarska M; Mah JK; Mongini TE; Ricci F; von der Hagen M; Finkel RS; O'Reardon K; Wicklund M; Kumar A; McDonald CM; Han JJ; Joyce N; Henricson EK; Schara-Schmidt U; Gangfuss A; Wilichowski E; Barohn RJ; Statland JM; Campbell C; Vita G; Vita GL; Howard JF; Hughes I; McMillan HJ; Pegoraro E; Bello L; Burnette WB; Thangarajh M; Chang T
    JAMA; 2022 Apr; 327(15):1456-1468. PubMed ID: 35381069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy.
    Ricotti V; Ridout DA; Scott E; Quinlivan R; Robb SA; Manzur AY; Muntoni F;
    J Neurol Neurosurg Psychiatry; 2013 Jun; 84(6):698-705. PubMed ID: 23250964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcomes of steroid therapy for Duchenne muscular dystrophy in Japan.
    Goto M; Komaki H; Takeshita E; Abe Y; Ishiyama A; Sugai K; Sasaki M; Goto Y; Nonaka I
    Brain Dev; 2016 Oct; 38(9):785-91. PubMed ID: 27112384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth, bone health & ambulatory status of boys with DMD treated with daily vs. intermittent oral glucocorticoid regimen.
    Crabtree NJ; Adams JE; Padidela R; Shaw NJ; Högler W; Roper H; Hughes I; Daniel A; Mughal MZ
    Bone; 2018 Nov; 116():181-186. PubMed ID: 30055340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
    Smith EC; Conklin LS; Hoffman EP; Clemens PR; Mah JK; Finkel RS; Guglieri M; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; Kerchner L; Morgenroth LP; Arrieta A; Shimony M; Jaros M; Shale P; Gordish-Dressman H; Hagerty L; Dang UJ; Damsker JM; Schwartz BD; Mengle-Gaw LJ; McDonald CM;
    PLoS Med; 2020 Sep; 17(9):e1003222. PubMed ID: 32956407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prednisolone treatment for Duchenne muscular dystrophy].
    Shimomura H; Fujii T; Miyajima T; Kumada T; Kimura N; Oda N; Saito K
    No To Hattatsu; 2011 Jan; 43(1):24-9. PubMed ID: 21400928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A 30-Month Nonrandomized Controlled Open-Label Extension Trial.
    Mah JK; Clemens PR; Guglieri M; Smith EC; Finkel RS; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; McDonald CM; Damsker JM; Schwartz BD; Mengle-Gaw LJ; Jackowski S; Stimpson G; Ridout DA; Ayyar-Gupta V; Baranello G; Manzur AY; Muntoni F; Gordish-Dressman H; Leinonen M; Ward LM; Hoffman EP; Dang UJ;
    JAMA Netw Open; 2022 Jan; 5(1):e2144178. PubMed ID: 35076703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cessation of ambulation results in a dramatic loss of trabecular bone density in boys with Duchenne muscular dystrophy (DMD).
    Crabtree NJ; Roper H; Shaw NJ
    Bone; 2022 Jan; 154():116248. PubMed ID: 34718220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiorespiratory Progression Over 5 Years and Role of Corticosteroids in Duchenne Muscular Dystrophy: A Single-Site Retrospective Longitudinal Study.
    Trucco F; Domingos JP; Tay CG; Ridout D; Maresh K; Munot P; Sarkozy A; Robb S; Quinlivan R; Riley M; Burch M; Fenton M; Wallis C; Chan E; Abel F; Manzur AY; Muntoni F
    Chest; 2020 Oct; 158(4):1606-1616. PubMed ID: 32387519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth pattern trajectories in boys with Duchenne muscular dystrophy.
    Stimpson G; Raquq S; Chesshyre M; Fewtrell M; Ridout D; Sarkozy A; Manzur A; Ayyar Gupta V; De Amicis R; Muntoni F; Baranello G;
    Orphanet J Rare Dis; 2022 Jan; 17(1):20. PubMed ID: 35073949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantifying Variability in Motor Function in Duchenne Muscular Dystrophy: UK Centiles for the NorthStar Ambulatory Assessment, 10 m Walk Run Velocity and Rise from Floor Velocity in GC Treated Boys.
    Stimpson G; Ridout D; Wolfe A; Milev E; O'Reilly E; Manzur A; Sarkozy A; Muntoni F; Cole TJ; Baranello G;
    J Neuromuscul Dis; 2024; 11(1):153-166. PubMed ID: 37980680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends in steroid therapy for Duchenne muscular dystrophy in Japan.
    Takeuchi F; Komaki H; Nakamura H; Yonemoto N; Kashiwabara K; Kimura E; Takeda S
    Muscle Nerve; 2016 Oct; 54(4):673-80. PubMed ID: 26910583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prednisolone in Duchenne muscular dystrophy with imminent loss of ambulation.
    Pradhan S; Ghosh D; Srivastava NK; Kumar A; Mittal B; Pandey CM; Singh U
    J Neurol; 2006 Oct; 253(10):1309-16. PubMed ID: 16786214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy.
    Mazzone E; Martinelli D; Berardinelli A; Messina S; D'Amico A; Vasco G; Main M; Doglio L; Politano L; Cavallaro F; Frosini S; Bello L; Carlesi A; Bonetti AM; Zucchini E; De Sanctis R; Scutifero M; Bianco F; Rossi F; Motta MC; Sacco A; Donati MA; Mongini T; Pini A; Battini R; Pegoraro E; Pane M; Pasquini E; Bruno C; Vita G; de Waure C; Bertini E; Mercuri E
    Neuromuscul Disord; 2010 Nov; 20(11):712-6. PubMed ID: 20634072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrospective cohort study comparing the efficacy of prednisolone and deflazacort in children with muscular dystrophy: A 6 years' experience in a South Indian teaching hospital.
    Petnikota H; Madhuri V; Gangadharan S; Agarwal I; Antonisamy B
    Indian J Orthop; 2016 Sep; 50(5):551-557. PubMed ID: 27746500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prednisolone therapy in Duchenne muscular dystrophy prolongs ambulation and prevents scoliosis.
    Yilmaz O; Karaduman A; Topaloğlu H
    Eur J Neurol; 2004 Aug; 11(8):541-4. PubMed ID: 15272899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.